BioDelivery Sciences International Inc. (BDSI) – One Step Closer to FDA Approval and Boosting Company Value
BioDelivery Sciences International Inc. (Nasdaq: BDSI) is a specialty pharmaceutical company focused on the development of innovative products for pain management. The company has two products in development utilizing its patented BEMA oral adhesive film technology: ONSOLIS, for pain in opioid-tolerant patients with cancer, and BEMA Buprenorphine, for the treatment of moderate to severe pain. BioDelivery today delivered news it has received a response letter from the U.S. Food and Drug Administration (FDA) regarding the company’s New Drug Application (NDA) for BEMA Fentanyl, which the company intends to market in the United States as ONSOLIS (fentanyl buccal soluble film). The…